Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2024 Aug 11;17(8):1057.
doi: 10.3390/ph17081057.

Hypoxia as a Target for Combination with Transarterial Chemoembolization in Hepatocellular Carcinoma

Zizhuo Wang  1 , Qing Li  2 , Bin Liang  1
Affiliations
Review

Hypoxia as a Target for Combination with Transarterial Chemoembolization in Hepatocellular Carcinoma

Zizhuo Wang et al. Pharmaceuticals (Basel). .

Abstract

Hypoxia is a hallmark of solid tumors, including hepatocellular carcinoma (HCC). Hypoxia has proven to be involved in multiple tumor biological processes and associated with malignant progression and resistance to therapy. Transarterial chemoembolization (TACE) is a well-established locoregional therapy for patients with unresectable HCC. However, TACE-induced hypoxia regulates tumor angiogenesis, energy metabolism, epithelial-mesenchymal transition (EMT), and immune processes through hypoxia-inducible factor 1 (HIF-1), which may have adverse effects on the therapeutic efficacy of TACE. Hypoxia has emerged as a promising target for combination with TACE in the treatment of HCC. This review summarizes the impact of hypoxia on HCC tumor biology and the adverse effects of TACE-induced hypoxia on its therapeutic efficacy, highlighting the therapeutic potential of hypoxia-targeted therapy in combination with TACE for HCC.

Keywords: hepatocellular carcinoma; hypoxia; hypoxia-inducible factor; transarterial chemoembolization; tumor microenvironment.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

References

    1. Vogel A., Meyer T., Sapisochin G., Salem R., Saborowski A. Hepatocellular carcinoma. Lancet. 2022;400:1345–1362. doi: 10.1016/S0140-6736(22)01200-4. - DOI - PubMed
    1. Reig M., Forner A., Rimola J., Ferrer-Fabrega J., Burrel M., Garcia-Criado A., Kelley R.K., Galle P.R., Mazzaferro V., Salem R., et al. BCLC strategy for prognosis prediction and treatment recommendation: The 2022 update. J. Hepatol. 2022;76:681–693. doi: 10.1016/j.jhep.2021.11.018. - DOI - PMC - PubMed
    1. Zeng H., Chen W., Zheng R., Zhang S., Ji J.S., Zou X., Xia C., Sun K., Yang Z., Li H., et al. Changing cancer survival in China during 2003-15: A pooled analysis of 17 population-based cancer registries. Lancet Glob. Health. 2018;6:e555–e567. doi: 10.1016/S2214-109X(18)30127-X. - DOI - PubMed
    1. Park J.-W., Chen M., Colombo M., Roberts L.R., Schwartz M., Chen P.-J., Kudo M., Johnson P., Wagner S., Orsini L.S., et al. Global patterns of hepatocellular carcinoma management from diagnosis to death: The BRIDGE Study. Liver Int. 2015;35:2155–2166. doi: 10.1111/liv.12818. - DOI - PMC - PubMed
    1. Galle P.R., Forner A., Llovet J.M., Mazzaferro V., Piscaglia F., Raoul J.-L., Schirmacher P., Vilgrain V. EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma. J. Hepatol. 2018;69:182–236. doi: 10.1016/j.jhep.2018.03.019. - DOI - PubMed

LinkOut - more resources